Changes in cell markers can help generate a regeneration hypothesis, but they are not themselves proof of clinical skin rejuvenation. This study examined that early biological level. Primary study
What was studied
Copper-GHK increased proliferation in cultured keratinocytes. In skin-equivalent models, investigators observed changes in basal-cell shape and increased PCNA, p63, and integrin alpha6 and beta1 measures. The experiments used laboratory cultures and reconstructed skin models rather than a patient treatment trial. Primary report
Our appraisal: a marker is not a complete cell identity or function
A marker associated with proliferation or a cell population can indicate a change worth investigating. It does not, by itself, show that a tissue has acquired all the functions associated with that population. Expression, cell number, lineage, and long-term behavior are distinct questions.
For the same reason, increased p63 positivity should not be simplified to creation of new stem cells. Establishing that claim would require appropriate identity and functional evidence, not just an increase in staining. Similarly, faster proliferation does not automatically mean better organization or a stronger barrier.
Skin-equivalent models provide more structural context than a single cell layer, but they remain simplified systems. Their value lies in controlled comparisons and accessible measurements. They do not reproduce every feature of living skin, including its full circulation, immune environment, innervation, and exposure history.
A clinical claim would require a bridge from these cellular observations to an outcome people can experience or measure reliably, such as a validated change in barrier function or a defined wound endpoint. That bridge cannot be supplied merely by using the word regenerative.
The study contributes mechanistic evidence about keratinocyte responses to copper-GHK. It does not establish anti-aging efficacy, a stem-cell treatment, or equivalence among topical and injectable products. Keeping marker changes distinct from functional recovery is the key to reading it accurately.
Frequently asked questions
Was this a patient trial?
No.
What cells were examined?
Keratinocytes.
Were reconstructed skin models used?
Yes.
Did proliferation-related measures increase?
Yes, under the tested conditions.
Does p63 positivity prove new stem-cell creation?
No.
Does more proliferation guarantee better skin function?
No.
What is the study's evidence level?
Laboratory mechanistic evidence rather than clinical efficacy.